Bristol-Myers Squibb vs Toyota: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Toyota was founded in 1937 by Kiichiro Toyoda, Sakichi Toyoda and is led by Kenta Kon.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Toyota
- Founded
- 1937
- Headquarters
- Toyota City, Aichi, Japan
- Current CEO
- Kenta Kon
- Employees
- 375,235
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Toyota
Kiichiro Toyoda
Kiichiro Toyoda (1894-1952) founded the Toyota Motor Corporation in 1937, spinning it out of his father's successful textile machinery business.
Sakichi Toyoda
Sakichi Toyoda was not the founder of Toyota Motor Corporation but his inventions and philosophy created the foundation on which it was built. His loom patents generated the capital Kiichiro needed to experiment with automobiles.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Toyota
- Akio Toyoda2009–2023
President and Chief Executive Officer (now Chairman)
Akio Toyoda took leadership during one of Toyota's hardest modern periods, including the global financial crisis and the unintended acceleration recall crisis.
Source - Koji Sato2023–2026
President and Chief Executive Officer (now Vice Chairman)
Koji Sato inherited a profitable but scrutinized Toyota.
Source - Kenta Kon2026–present
President and Chief Executive Officer
As CFO, he managed the immense capital allocation required for Toyota's massive $35 billion commitment to fully electrify its vehicle lineup by 2030.
Source
Timeline: Bristol-Myers Squibb and Toyota side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1937Toyota
Toyota Motor Corporation incorporated
Toyota Motor Corporation was incorporated after Kiichiro Toyoda expanded the Toyoda family business from automatic looms into automobile manufacturing.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1955Toyota
Toyopet Crown launched
The Toyopet Crown gave Toyota a postwar passenger-car platform and later became its first passenger car exported to the United States.
1966Toyota
Corolla launched
Toyota launched the Corolla, a compact car that became central to its mass-market export strategy.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1989Toyota
Lexus launches
Toyota launched Lexus with the LS 400, moving into premium vehicles with a quality-led strategy.
1997Toyota
Prius launches in Japan
Toyota launched the Prius, turning hybrid technology into a mass-produced passenger vehicle.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2016Toyota
Acquired Daihatsu Motor Co., Ltd.
Toyota Motor acquired Daihatsu Motor Co., Ltd..
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2021Toyota
Acquired Lyft Level 5
Toyota Motor acquired Lyft Level 5 for $550 million.
2021Toyota
Acquired CARMERA
Toyota Motor acquired CARMERA.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Toyota
Kenta Kon becomes president and CEO
Kenta Kon became president and CEO on April 1, 2026, while Koji Sato moved to vice chairman and chief industry officer.
2026Toyota
FY2026 sales revenues reach ~$340B (JPY 50.685T)
Toyota reported FY2026 sales revenues of ~$340 billion (JPY 50,684.952 billion) and net income attributable to Toyota Motor Corporation of ~$25.8 billion (JPY 3,848.098 billion).
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Toyota
- Lyft Level 52021$550M
- CARMERA2021Undisclosed
- Renovo Motors2021Undisclosed
- Daihatsu Motor Co., Ltd.2016Undisclosed
- Toyota Auto Body2012Undisclosed
Questions about Bristol-Myers Squibb vs Toyota
Who is the CEO of Bristol-Myers Squibb Company and Toyota Motor Corporation?
Bristol-Myers Squibb Company is led by Christopher Boerner and Toyota Motor Corporation is led by Kenta Kon. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Toyota Motor Corporation?
Bristol-Myers Squibb Company was founded in 1887 — 50 years before Toyota Motor Corporation, which was founded in 1937. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Toyota Motor Corporation.
How many employees does Bristol-Myers Squibb Company have compared to Toyota Motor Corporation?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Toyota Motor Corporation employs approximately 375,235. Toyota Motor Corporation has the larger workforce at 375,235 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Toyota Motor Corporation headquartered?
Bristol-Myers Squibb Company is headquartered in United States and Toyota Motor Corporation is headquartered in Japan. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Bristol-Myers Squibb Company and Toyota Motor Corporation?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Toyota Motor Corporation was founded by Kiichiro Toyoda, Sakichi Toyoda.
Which company has a longer operating history — Bristol-Myers Squibb Company or Toyota Motor Corporation?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Toyota Motor Corporation has been in operation for around 89 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Toyota overview